What question did this study set out to answer?

The aim is to explore FDA's initiatives to facilitate biosimilar approvals and promote their use.

March 12, 2026

FDA’s Regulatory Reforms to Unlock Competition and Lower Drug Costs

Key Points

The aim is to explore FDA's initiatives to facilitate biosimilar approvals and promote their use.
Discussed regulatory changes by the FDA
Analyzed criteria for biosimilar approvals
Examined potential impact on drug pricing and availability
Removal of burdensome criteria could lead to faster biosimilar approvals
Encouraging biosimilars over branded drugs may lower treatment costs
Greater access to biosimilars for patients is anticipated

Abstract

This Viewpoint from the FDA explains efforts to remove burdensome criteria for biosimilar approvals and encourage use of biosimilars over branded biologics, which could lead to greater access to biosimilars for patients and reduce treatment costs.

Mark Helpful

Bookmark

Relay